Navigation Links
Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference
Date:11/30/2011

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011.  The conference will be held at the Westin Copley Place in Boston, MA.  Dr. Spana will be presenting an overview on Palatin's Phase 2b trial for bremelanotide in premenopausal women with female sexual dysfunction, and the Phase 1 trial for AZD2820, under development for the treatment of obesity, in collaboration with AstraZeneca.  Bremelanotide, the Company's lead drug candidate, was named one of the "2011 Top Projects to Watch" by Windhover.

ABOUT THE CONFERENCE

Windhover's Therapeutic Area Partnerships conference is a uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking. For more information on the conference and presenting companies please go to http://www.tapartnerships.com.  

ABOUT PALATIN TECHNOLOGIES, INC.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.


 

 


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at 10th Annual BIO Investor Forum
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
5. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
6. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
8. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
9. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
10. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
11. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today its ... the Annual Biocom Global Life Science Partnering Conference.  The ... AM, at the Torrey Pines Lodge, in San Diego.  ... at Biocom who have chosen our company, amongst numerous ... companies, investors, and clinical researchers," said Mr. Chen. "In ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... around the world, is pleased to announce the 2nd annual Precision Medicine Virtual ... premier, online-only conference focused on the development and advancements in precision medicine. , ...
(Date:2/22/2017)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), ... the ability of the Aethlon Hemopurifier® to capture latent ... immune-suppressed sepsis patients and also contribute to organ rejection ... the study was to validate the in vitro ... Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The ...
(Date:2/22/2017)... N.C., Feb. 22, 2017  United Therapeutics Corporation (NASDAQ: ... results for the fourth quarter and year ended ... results reflect continued growth as net revenues reached ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and Chief ... to develop and advance our growing product pipeline, ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
Breaking Biology News(10 mins):